Boehringer Ingelheim

This study tested a single dose of an inhaled gene therapy called BI 3720931 in adults with cystic fibrosis who cannot use standard CFTR modulator drugs. The goal was to see if it was safe and could improve lung function. The study was terminated early after enrolling only 5 part…

This early-stage study tested a new drug called BI 765883, given alone or with chemotherapy, for people with advanced pancreatic cancer that had spread or returned. The goal was to find a safe dose and see if it could shrink tumors. The study was terminated early after enrolling …

This study aimed to collect real-world safety and effectiveness data on Pradaxa Pellets for treating blood clots in children aged 3 months to 12 years. It planned to track bleeding events and clot recurrence. However, the study was terminated early and only enrolled 6 participant…

This study tested a new medicine called BI 765845 in adults who recently had a heart attack. The goal was to see if it could reduce heart muscle damage when added to standard care. Participants received either the drug or a placebo and were monitored for 3 months. The study was t…

This study looked at the long-term safety of the drug iclepertin in adults with schizophrenia who had already completed a previous iclepertin trial. Participants took iclepertin once a day for a year, along with their regular schizophrenia medication. The main goal was to track a…

This study tested a medicine called spesolimab in people aged 12 and older with Netherton syndrome, a rare genetic skin condition causing redness and scaling. Participants received either spesolimab or a placebo injection, with the placebo group switching to the real drug after 4…

This study looked at how a new drug (BI 1819479) is absorbed, broken down, and removed from the body in healthy male volunteers. The goal was to understand the drug's behavior, not to treat any disease. The study was terminated early, and only 7 participants were enrolled.

This study used special PET scans to see where an experimental cancer drug goes in the body and how much reaches tumors. It involved 8 adults with advanced lung or head/neck cancer. The goal was to learn about the drug's distribution, not to treat the disease directly.

This study looked at how healthy men absorb, break down, and eliminate a new drug called BI 1839100. It had two parts: one measured how much of the drug and its radioactive tracer was recovered in urine and stool after an oral dose, and the other compared the drug's availability …

This early-stage study aimed to check the safety and how the body handles multiple doses of an experimental drug called BI 3731579. It involved 30 healthy adults aged 18 to 55 who took the drug daily for 15 days. The trial was terminated early, so results are limited.